Translating in vivo diagnostics into clinical reality

Article Abstract:

The Food and Drug Administration (FDA) has approved only five new in vivo diagnostic agents since 2001, out of which it two were withdrawn from market. The factors that impede translations of promising in vivo diagnostic to patients, and the limitations of current technologies of molecular imaging techniques are discussed.

Government regulation, In-Vitro Diagnostic Substance Manufacturing, Diagnostic substances, Diagnostic Chemicals, Diagnostic Reagents, Licensing, certification and accreditation, United States. Food and Drug Administration

---

Self-illuminating quantum dots light the way

Article Abstract:

A new quantum dot technology that permits improved imaging in vivo compared with existing quantum dots, where the new probes rely on bioluminescence resonance energy transfer is illustrated. Bioluminescent quantum dot technology improves near-infrared fluorescence detection in living tissue.

Usage, Bioluminescence, Energy transformation, Luciferase

---

Renal clearance of quantum dots

Article Abstract:

Intravenously administered quantum dots are used as a model system for defining the requirements for renal filtration and urinary excretion of inorganic, metal-containing nanoparticles.

Models, Physiological aspects, Quantum theory, Quantum mechanics, Hydrodynamics, Excretion, Hydrofoil boats, Nanoparticles, Report

Similar abstracts:

• Abstracts: Boeing leader voices no concern QDR will entail canceling programs. Boeing leader urges multi-contractor, multi-national programs
• Abstracts: Private equity investing in India shifts into high gear. Aviation sector takes off. Forex reserves surge with flood of investment
• Abstracts: The World Wide Web as an industrial marketing communication tool: models for the identification and assessment of opportunities
• Abstracts: Deconstructing Myogen's market cap. Niche indications could drive higher valuations. Are small biotechs still underselling themselves?
• Abstracts: Gold in the ivory tower: Equity rewards of outlicensing. Who took the tech out of biotech? The hermit crab solution

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.